Phase 1 Clinical Data of Innovent's IBI363 at 2024 ASCO Annual Meeting
Saturday, 1 June 2024, 21:12
Innovent IBI363 Clinical Data Presentation
Innovent presented the Phase 1 clinical data of its innovative PD-1/IL-2α bispecific antibody fusion protein, IBI363, at the 2024 ASCO Annual Meeting.
Promising Results for Solid Tumor Treatment
The findings highlight the potential of IBI363 in improving outcomes for patients with melanoma, colorectal cancer, and other solid tumors.
- Breakthrough Therapy: IBI363 offers new hope for more effective treatments.
- Better Survival Rates: The results suggest improved survival rates in difficult-to-treat cancers.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.